multiplan - MPLN
MPLN
Close Chg Chg %
7.06 -0.45 -6.37%
Open Market
6.61
-0.45 (6.37%)
Volume: 27.81K
Last Updated:
Nov 22, 2024, 11:58 AM EDT
Company Overview: multiplan - MPLN
MPLN Key Data
| Open $7.10 | Day Range 6.57 - 7.17 |
| 52 Week Range 4.80 - 69.20 | Market Cap $104.30M |
| Shares Outstanding 16.17M | Public Float 6.56M |
| Beta 0.64 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$95.37 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 79.13K |
MPLN Performance
| 1 Week | 13.59% | ||
| 1 Month | -27.55% | ||
| 3 Months | -31.12% | ||
| 1 Year | -86.50% | ||
| 5 Years | N/A |
MPLN Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
3
Full Ratings ➔
About multiplan - MPLN
MultiPlan Corp. engages in providing data analytics and technology-enabled solutions. It focuses on analytics-based services, data and decision science services, network-based services, payment and revenue integrity services, surprise billing services, and MultiPlan payments. The company was founded in 1980 and is headquartered in New York, NY.
MPLN At a Glance
MultiPlan Corp.
115 Fifth Avenue
New York, New York 10003
| Phone | 1-212-780-2000 | Revenue | 961.52M | |
| Industry | Data Processing Services | Net Income | -91,697,000.00 | |
| Sector | Technology Services | Employees | 2,800 | |
| Fiscal Year-end | 12 / 2024 | |||
| View SEC Filings |
MPLN Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 0.966 |
| Price to Book Ratio | 0.546 |
| Price to Cash Flow Ratio | 5.41 |
| Enterprise Value to EBITDA | 9.038 |
| Enterprise Value to Sales | 5.632 |
| Total Debt to Enterprise Value | 0.844 |
MPLN Efficiency
| Revenue/Employee | 343,401.429 |
| Income Per Employee | -32,748.929 |
| Receivables Turnover | 12.559 |
| Total Asset Turnover | 0.132 |
MPLN Liquidity
| Current Ratio | 1.161 |
| Quick Ratio | 1.161 |
| Cash Ratio | 0.489 |
MPLN Profitability
| Gross Margin | 31.829 |
| Operating Margin | 18.034 |
| Pretax Margin | -11.134 |
| Net Margin | -9.537 |
| Return on Assets | -1.258 |
| Return on Equity | -5.24 |
| Return on Total Capital | -1.461 |
| Return on Invested Capital | -1.431 |
MPLN Capital Structure
| Total Debt to Total Equity | 267.266 |
| Total Debt to Total Capital | 72.772 |
| Total Debt to Total Assets | 64.286 |
| Long-Term Debt to Equity | 266.21 |
| Long-Term Debt to Total Capital | 72.484 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Multiplan - MPLN
Collapse All in section
| All values USD millions. | 2020 | 2021 | 2022 | 2023 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 937.76M | 1.12B | 1.08B | 961.52M | |
Sales Growth
| -4.59% | +19.18% | -3.39% | -10.95% | |
Cost of Goods Sold (COGS) incl D&A
| 713.95M | 580.39M | 613.39M | 655.49M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 403.68M | 412.06M | 415.66M | 425.79M | |
Depreciation
| 68.98M | 71.85M | 75.12M | 83.09M | |
Amortization of Intangibles
| 334.70M | 340.21M | 340.54M | 342.69M | |
COGS Growth
| +32.34% | -18.71% | +5.69% | +6.86% | |
Gross Income
| 223.81M | 537.22M | 466.33M | 306.04M | |
Gross Income Growth
| -49.53% | +140.03% | -13.20% | -34.37% | |
Gross Profit Margin
| +23.87% | +48.07% | +43.19% | +31.83% |
| 2020 | 2021 | 2022 | 2023 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 355.63M | 131.99M | 132.14M | 132.63M | |
Research & Development
| - | - | - | - | - |
Other SG&A
| 355.63M | 131.99M | 132.14M | 132.63M | |
SGA Growth
| +372.76% | -62.89% | +0.12% | +0.37% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| 67.57M | 2.35M | 595.31M | (44.51M) | |
EBIT after Unusual Expense
| (199.39M) | 402.87M | (261.13M) | 217.91M | |
Non Operating Income/Expense
| (11.88M) | 55.00K | 3.79M | 8.23M | |
Non-Operating Interest Income
| 288.00K | 30.00K | 3.50M | 8.23M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 335.64M | 267.48M | 303.40M | 333.21M | |
Interest Expense Growth
| -10.82% | -20.31% | +13.43% | +9.82% | |
Gross Interest Expense
| 335.64M | 267.48M | 303.40M | 333.21M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (546.91M) | 135.45M | (560.74M) | (107.06M) | |
Pretax Income Growth
| -5,304.18% | +124.77% | -513.98% | +80.91% | |
Pretax Margin
| -58.32% | +12.12% | -51.93% | -11.13% | |
Income Tax
| (26.34M) | 33.37M | 12.17M | (15.36M) | |
Income Tax - Current - Domestic
| 18.70M | 115.30M | 126.55M | 98.70M | |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| (45.04M) | (81.93M) | (114.38M) | (114.06M) | |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (520.56M) | 102.08M | (572.91M) | (91.70M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (520.56M) | 102.08M | (572.91M) | (91.70M) | |
Net Income Growth
| -5,461.11% | +119.61% | -661.24% | +83.99% | |
Net Margin Growth
| -55.51% | +9.13% | -53.06% | -9.54% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (520.56M) | 102.08M | (572.91M) | (91.70M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (520.56M) | 102.08M | (572.91M) | (91.70M) | |
EPS (Basic)
| -44.2296 | 6.272 | -35.8672 | -5.6856 | |
EPS (Basic) Growth
| -4,833.48% | +114.18% | -671.86% | +84.15% | |
Basic Shares Outstanding
| 11.77M | 16.28M | 15.97M | 16.13M | |
EPS (Diluted)
| -44.2296 | 6.2672 | -35.8672 | -5.6856 | |
EPS (Diluted) Growth
| -4,833.48% | +114.17% | -672.30% | +84.15% | |
Diluted Shares Outstanding
| 11.77M | 16.29M | 15.97M | 16.13M | |
EBITDA
| 271.86M | 817.28M | 749.84M | 599.19M | |
EBITDA Growth
| -64.59% | +200.63% | -8.25% | -20.09% | |
EBITDA Margin
| +28.99% | +73.13% | +69.45% | +62.32% |
Snapshot
| Average Recommendation | OVERWEIGHT | Average Target Price | 30.00 | |
| Number of Ratings | 3 | Current Quarters Estimate | -9.81 | |
| FY Report Date | 12 / 2024 | Current Year's Estimate | -80.714 | |
| Last Quarter’s Earnings | -24.25 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -5.60 | Next Fiscal Year Estimate | -8.685 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 3 | 1 | 3 | 3 |
| Mean Estimate | -9.81 | -2.14 | -80.71 | -8.68 |
| High Estimates | -2.33 | -2.14 | -49.91 | -5.92 |
| Low Estimate | -23.93 | -2.14 | -96.59 | -12.05 |
| Coefficient of Variance | -124.72 | N/A | -33.06 | -35.83 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 1 | 1 | 1 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 2 | 2 | 2 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Overweight | Overweight | Overweight |
SEC Filings for Multiplan - MPLN
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Multiplan - MPLN
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Jun 5, 2024 | Carol H. Nutter SVP, Chief People Officer | 555,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 5, 2024 | Carol H. Nutter SVP, Chief People Officer | 733,500 | Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $1.11 per share | 814,185.00 |
| May 21, 2024 | Anthony Colaluca Director | 220,000 | Open market or private purchase of non-derivative security Non-derivative transaction at $0.6 per share | 132,000.00 |
| Apr 29, 2024 | C. Martin Harris Director | 318,003 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 29, 2024 | Richard A. Clarke Director | 320,082 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 29, 2024 | Michael Stuart Klein Director | 320,082 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 29, 2024 | Julie D. Klapstein Director | 331,171 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 29, 2024 | John Michael Prince Director | 213,174 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 29, 2024 | Glenn Russell August Director | 320,082 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 21, 2024 | Travis S. Dalton Chief Executive Officer; Director | 4,504,504 | Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $1.11 per share | 4,999,999.44 |
| Mar 21, 2024 | Travis S. Dalton Chief Executive Officer; Director | 6,849,315 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 13, 2024 | Jerry Hogge EVP, Chief Operating Officer | 1,041,667 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 6, 2024 | Dale A. White Executive Chair; Director | 14,990,354 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $1.11 per share | 16,639,292.94 |
| Mar 6, 2024 | Dale A. White Executive Chair; Director | 15,666,029 | Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $1.11 per share | 17,389,292.19 |
| Mar 6, 2024 | Jeffrey A. Doctoroff EVP, General Counsel | 1,233,163 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $1.11 per share | 1,368,810.93 |
| Mar 6, 2024 | Jeffrey A. Doctoroff EVP, General Counsel | 1,169,916 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $1.11 per share | 1,298,606.76 |
| Mar 6, 2024 | Dale A. White Executive Chair; Director | 15,636,810 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $1.11 per share | 17,356,859.10 |
| Mar 6, 2024 | Gerald J. Kozel SVP, Chief Accounting Officer | 830,865 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $1.11 per share | 922,260.15 |
| Mar 6, 2024 | Nutter Carol SVP, Chief People Officer | 733,500 | Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $1.11 per share | 814,185.00 |
| Mar 6, 2024 | Michael C. Kim SVP, Chief Information Officer | 983,286 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $1.11 per share | 1,091,447.46 |
Multiplan in the News
Covid-19 charges at hospitals can vary by tens of thousands of dollars, a WSJ analysis finds
The cost of similar Covid-19 treatments can vary by tens of thousands of dollars a patient, even within the same hospital, according to a Wall Street Journal analysis of pricing data that indicates pandemic care hasn’t escaped the complex economics of the U.S. health system.